Bio-Techne Sets September 23 Shareholder Vote on $73/Share Merck KGaA Merger
TECH sits 67% above its 52-week low of $43.195.
Summary
Bio-Techne's definitive proxy sets a September 23 shareholder vote on the $73 per share all-cash acquisition by Merck KGaA, with U.S. antitrust review still pending after an HSR refiling.
Key Events · M&A and Partnerships · TECH
-
Shareholder Vote Set for September 23
Special meeting scheduled for September 23, 2026 at 9:00 a.m. ET, with record date August 11, 2026 and 156,800,296 shares outstanding.
-
Merger Consideration Unchanged at $73/Share
Each outstanding share will be converted into $73.00 in cash, representing a 24% premium to the June 24, 2026 closing price of $58.88.
-
HSR Review Extended
Parent voluntarily withdrew its HSR notification on August 17, 2026 to give the FTC more time, and refiled on August 19, 2026, pushing the regulatory timeline.
-
German Antitrust Approval Secured
The German Federal Cartel Office approved the acquisition on August 17, 2026, clearing a key international regulatory hurdle.
Analysis · TECH · Life Sciences
The definitive proxy statement locks in the shareholder vote date and reveals that the HSR waiting period was voluntarily withdrawn and refiled, extending the regulatory review timeline. The $73.00 per share all-cash consideration remains unchanged from the June 25 announcement, but the filing adds material procedural details: a September 23 special meeting, a record date of August 11 with 156.8 million shares outstanding, and updated regulatory status. The German Federal Cartel Office has already approved the deal, but U.S. antitrust review is still ongoing. Shareholders now have a concrete date to vote on a transaction that offers a 24% premium to the pre-announcement price.
At the time of this filing, TECH was trading at $72.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.3B. The 52-week trading range was $43.20 to $72.62. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.